Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Publication of the first issue of Quantum Genomics' shareholder newsletter - June, 2016



Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces the publication of its first shareholder newsletter.


Contents of this first issue:



  • A word from Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics : “2016 stands to be a year full of promise, with the international deployment of ambitious clinical trials.”

  • Recent news : Quantum Genomics Symposium at the European Meeting on Hypertension and Cardiovascular Protection

  • Zoom : Development in the United States

  • Portrait : Docteur Keith C.Ferdinand

  • Shareholder guide

The shareholder newsletter is available on the company's website at www.quantum-genomics.com, in the Shareholder letters section of the Investors tab.


Next meeting : General Shareholders' Meeting on 15 June 2016, at 10:00 am.








CONTACTS

Quantum Genomics


Lionel Ségard

Chairman & Chief Executive Officer

+33 1 85 34 77 77

 

Quantum Genomics

Marc Karako

CFO – Investor Relations

+33 1 85 34 77 75

[email protected]

 

ACTUS finance & communication (Europe)

Jean-Michel Marmillon

Press Relations

+33 1 53 67 36 73 / [email protected]

 

The Ruth Group (U.S.)

Lee Roth / Kirsten Thomas

Investor / Public Relations

+1 646-536-7012 / +1 508-280-6592

 







ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.

 

Information réglementée
Communiqués au titre de l'obligation d'information permanente :

- Autres communiqués

Full and original press release in PDF:


https://www.actusnews.com/documents_communiques/ACTUS-0-44479-QUANTUM_CP_Parution-LAA_02062016_VDEF_EN.pdf

© Copyright Actusnews Wire

Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free



Quelle: Actusnews

Quantum Genomics S.A. Stock

€0.11
16.120%
A very strong showing by Quantum Genomics S.A. today, with an increase of €0.016 (16.120%) compared to yesterday's price.

Like: 0
Share

Comments